← Leaderboards
Ivan O. Rosas
Brigham And Women'S Hospital
$7,752,634
Attributed
$17,714,543
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2008–25$2.5M$1.9M$1.3M$625K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,714,543 · 7
By mechanism
R01$10,086,388 · 2
U01$5,731,158 · 2
T32$1,137,592 · 2
K23$759,405 · 1
Top collaborators
- Gary Matthew Hunninghake8 shared
- Benjamin Alexander Raby8 shared
- Gerard J Criner5 shared
- Steven R Duncan5 shared
- Daniel J Kass5 shared
- Joe G. N. Garcia2 shared
- Farrah Kheradmand2 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Gary Matthew Hunninghake$13,432,772
- Hongtu Chen$3,916,439
- Jun Shen$600,750
- Sue E Levkoff$5,292,528
- Komatra Chuengsatiansup$228,463
Others in their field
Top investigators on “Lung”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$372,040,227
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$201,818,043
- Walter John Curran · Thomas Jefferson University$112,093,071
Research focus
LungMedicalCohortLung DiseasesDisease ProgressionFutureHamman-Rich SyndromeGenesInterstitial Lung DiseasesClinical TrialsPhysiologicalBaseFollow-UpEarly DiagnosisDiagnosisInterstitialPulmonary FibrosisOutcome ForecastPrevalenceScreeningProteinsPathogenesisMedicineCandidate Disease Gene
Grant awards (27)
Clinical Genetics and Screening for Pulmonary Fibrosis$1,283,458
R01 · FY2025 · HL
BCM-Respiratory Research Training$300,639
T32 · FY2025 · HL
Clinical Genetics and Screening for Pulmonary Fibrosis$1,320,990
R01 · FY2024 · HL
BCM-Respiratory Research Training$296,336
T32 · FY2024 · HL
Clinical Genetics and Screening for Pulmonary Fibrosis$1,385,234
R01 · FY2023 · HL
Clinical Genetics and Screening for Pulmonary Fibrosis$1,452,517
R01 · FY2022 · HL
Autoantibody-Targeted Therapy for Acute Exacerbations of Idiopathic Pulmonary Fibrosis$700,683
U01 · FY2021 · HL
Autoantibody-Targeted Therapy for Acute Exacerbations of Idiopathic Pulmonary Fibrosis$753,012
U01 · FY2020 · HL
Research Training in Lung Disease$72,955
T32 · FY2020 · HL · contact PI
Autoantibody-Targeted Therapy for Acute Exacerbations of Idiopathic Pulmonary Fibrosis$771,021
U01 · FY2019 · HL
Clinical Genetics and Screening for Pulmonary Fibrosis$763,525
R01 · FY2019 · HL
Research Training in Lung Disease$467,662
T32 · FY2019 · HL · contact PI
Clinical Genetics and Screening for Pulmonary Fibrosis$818,151
R01 · FY2018 · HL
Autoantibody-Targeted Therapy for Acute Exacerbations of Idiopathic Pulmonary Fibrosis$771,021
U01 · FY2018 · HL
Clinical Genetics and Screening for Pulmonary Fibrosis$876,901
R01 · FY2017 · HL
Autoantibody-Targeted Therapy for Acute Exacerbations of Idiopathic Pulmonary Fibrosis$787,346
U01 · FY2017 · HL
Clinical and Molecular Profiles of Smokers with Subclinical Interstitial Lung Disease$423,177
R01 · FY2017 · HL · contact PI
Clinical Genetics and Screening for Pulmonary Fibrosis$877,331
R01 · FY2016 · HL
Clinical and Molecular Profiles of Smokers with Subclinical Interstitial Lung Disease$423,177
R01 · FY2016 · HL · contact PI
Clinical and Molecular Profiles of Smokers with Subclinical Interstitial Lung Disease$461,927
R01 · FY2015 · HL · contact PI
Phase II Study of Inhales Carbon Monoxide for the Treatment of Idiopathic Pulmona$181,532
U01 · FY2014 · HL · contact PI
Phase II Study of Inhales Carbon Monoxide for the Treatment of Idiopathic Pulmona$1,766,543
U01 · FY2013 · HL · contact PI
Syndecan-2 and Clinical Progression of Idiopathic Pulmonary Fibrosis$151,881
K23 · FY2012 · HL · contact PI
Syndecan-2 and Clinical Progression of Idiopathic Pulmonary Fibrosis$151,881
K23 · FY2011 · HL · contact PI
Syndecan-2 and Clinical Progression of Idiopathic Pulmonary Fibrosis$151,881
K23 · FY2010 · HL · contact PI
Syndecan-2 and Clinical Progression of Idiopathic Pulmonary Fibrosis$151,881
K23 · FY2009 · HL · contact PI
Syndecan-2 and Clinical Progression of Idiopathic Pulmonary Fibrosis$151,881
K23 · FY2008 · HL · contact PI